Epigene Labs logo — augmented intelligence for precision oncology research and d...

Epigene Labs

augmented intelligence for precision oncology research and drug development

Founded 2019 France France 37 employees Convertible Note Total: $5.40M Biopharma, Biotechnology

General Information

Company Name Epigene Labs
Founded Year 2019
Location France France
Founders / Decision Makers
Team member Team member
Employees 37
Industries Biopharma, Biotechnology
Funding Stage Convertible Note
Social

BounceWatch is an independent company data service, not affiliated with Epigene Labs. To contact Epigene Labs, visit epigenelabs.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Epigene Labs compare?

A PDF of Epigene Labs and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Epigene Labs soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Epigene Labs

Epigene Labs is a Paris-based startup that has developed the mCUBE platform, which aims to revolutionize precision oncology research and drug development. Founded in 2019, the company's slogan "augmented intelligence for precision oncology research and drug development" captures the essence of their mission. Epigene Labs' mCUBE platform is tailored specifically for cancer scientists, empowering them to accelerate data-driven drug discovery, biomarker identification, and patient selection. This technology ultimately strives to bring improved treatments to patients more rapidly. Having initially been incubated at the Harvard Innovation Labs, Epigene Labs has gained significant traction and support from prominent European investors, as evidenced by their last investment of €1.50MConvertible Note investment at 29 September 2023 from the European Innovation Council. This backing has enabled the company to forge partnerships with esteemed cancer research institutes and biopharmaceutical companies, cementing its position as a key player in the biopharma and biotechnology industries. With a dual base in Paris and Boston, Epigene Labs is strategically positioned at the forefront of innovation in oncology research and drug development. As the company continues to grow and evolve, its cutting-edge solutions and influential network of partners are poised to make a lasting impact on the field of precision medicine.

Business keywords: Precision Oncology Research, Drug Development, Genomic Data Analysis, Biomarker Identification, Patient Selection, Cancer Research Institutes, Biopharmaceutical Partnerships, Data-Driven Drug Discovery, Paris and Boston Operations, Value-Based Partnerships, Sequencing Technologies, Harvard Innovation Labs, Biotech Collaborations

Services & Products

mCUBE platform for comprehensive omic research data and AI-driven insights for precision oncology R&D

Target Customers

Biopharmaceutical companies Research Institutes Clinical Research Organizations (CROs)

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Convertible Note €1.50M 1
European Innovation Council
29 Sep 2023
Grant €2.50M 1
European Innovation Council
06 Oct 2021
Seed Round €1.40M 2
Daphni, Majycc eSanté Invest
30 Jan 2020
Non Equity Assistance Undisclosed 1
AGORANOV
01 Jul 2019

Epigene Labs Alternatives & Competitors

View All Alternatives
Epigene Labs vs

Leveraging Artificial Intelligence to Rescue and Develop Cancer Therapies

Post-IPO Secondary
28 employees
AI, Biopharma
Epigene Labs vs

VCP/p97 Inhibitors for Oncology and Neurodegenerative Diseases

Series C
3 employees
Biopharma, Biotechnology
Epigene Labs vs

Cancer drug development comes of age.

Post-IPO Equity
190 employees
Biopharma, Biotechnology

FAQ About Epigene Labs

augmented intelligence for precision oncology research and drug development
Epigene Labs was founded in 2019.
Epigene Labs is headquartered in France.
Epigene Labs operates in Biopharma and Biotechnology. Its work centres on Precision Oncology Research, Drug Development, Genomic Data Analysis and Biomarker Identification. Its customers include Biopharmaceutical companies, Research Institutes and Clinical Research Organizations (CROs).
Epigene Labs has approximately 37 employees.
Epigene Labs has completed 4 funding rounds, raising a total of $5.40M. The latest funding stage is Convertible Note.
Epigene Labs offers: mCUBE platform for comprehensive omic research data and AI-driven insights for precision oncology R&D.
Top alternatives and competitors to Epigene Labs include Lantern Pharma Inc. (Nasdaq: LTRN), Cleave Therapeutics, Inc., Day One Biopharmaceuticals, OncXerna Therapeutics , Arno Therapeutics Inc (ARNI). These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Epigene Labs and Lantern Pharma Inc. (Nasdaq: LTRN) are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Epigene Labs, https://bouncewatch.com/company/epigene-labs, updated 7 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes